Business Wire

Shell Offers New AI-Powered Applications Through Open AI Energy Initiative

9.11.2021 17:00:00 EET | Business Wire | Press release

Share

C3 AI (NYSE:AI) and Shell (NYSE:RDS) today announced three new Shell products that will be available through the Open AI Initiative (OAI), an open ecosystem of artificial intelligence (AI)-based solutions for the energy and process industries.

The OAI, launched by C3 AI, Shell, Baker Hughes and Microsoft in February 2021, provides an open framework for energy operators, service & equipment providers, and independent software vendors to offer interoperable solutions, powered by the BHC3 AI Suite and Microsoft Azure. The three new OAI products – Shell Process Optimiser for LNG, Shell Corrosion Advanced Risk Modelling and Analytics, and Shell Autonomous Integrity Recognition – target use cases that will solve key challenges for businesses in the energy industry. By using Shell’s proven domain-specific AI applications built on BHC3’s scalable AI application development platform and SaaS applications, businesses can rapidly move past data discovery and cleaning to application deployment and realization of value in critical business areas.

Details on the new offerings are outlined below:

  • Shell Process Optimiser for LNG – The application marries state-of-the-art LNG process engineering and technology with data analytics to enhance asset production by helping asset engineers close the gap between current and optimal production (“gap to potential”) by changing key identified operating conditions as optimization levers. The application integrates sensor information, such as pressure, temperature, and flow rate to calculate the optimum setting using custom-built asset machine learning models. It reveals unknown correlations and sweet spots, and derives the best suitable strategies as optimization know-how. The application, capable of handling operational, economic, and engineering constraints, Shell Process Optimiser for LNG generates actionable insights that can be integrated and brought into the continuous closed loop process control layer for sustained benefits realisation.
  • Shell Corrosion Advanced Risk Modelling and Analytics – The application makes use of novel data analytics techniques to predict internal corrosion and erosion to better prioritize and target inspection and maintenance activities. By using a variety of collected site data, and with the help of artificial intelligence, the software provides new insights to predict corrosion and erosion and identify degradation before leaks happen. By using this solution, operators can lower inspection costs and HSSE risk, minimise cost of related leaks, and safely push production to the limit. Additionally, Shell Corrosion Advanced Risk Modelling and Analytics reduces the need for manual, tedious field inspections, resulting in significant time and cost savings.
  • Shell Autonomous Integrity Recognition – The application allows inspectors to quickly and easily make use of automated image capture and evaluation to support execution of external integrity inspections. By processing data in the cloud coming from inspections carried out with handheld devices, drones and robots, the solution enables inspectors to objectively evaluate issues, identify items that have been overlooked, reduce the time needed at the desk generating reports, and improve inputs to maintenance planning. Shell Autonomous Integrity Recognition application allows users to identify and classify external corrosion and insulation issues with Machine Vision to reduce leakages. By using this, users can improve the quality, efficiency, and standardization of visual inspections.

These products expand the portfolio of solutions available to OAI subscribers and help accelerate the adoption of enterprise AI in the energy and process industries.

“Previously, there was no framework for Oil and Gas operators to subscribe to proven AI and advanced analytic solutions offered by other operators,” said C3 AI CEO Thomas M. Siebel. “By bringing more solutions built on the BHC3 AI Suite to the OAI, Shell is demonstrating market leadership and establishing the OAI as a one-of-a-kind model of collaboration.”

These applications also broaden the focus areas of the OAI offerings from asset and system reliability to facility and plant optimization and asset integrity, adding to an expanding portfolio of highly differentiated, domain-specific and proven AI applications and modules that are interoperable. These applications can be deployed together to realize business value and create scalable, futureproof reference architectures.

“The products announced today have already been deployed at Shell and have been proven to either create operational efficiencies and savings or generate additional revenue and opportunity,” said Dan Jeavons, Vice President Computational Science and Digital Innovation at Shell. “As more products are added to the growing OAI eco-system, we look forward to working with C3 AI, Baker Hughes, and the other ecosystem partners to build the next-generation platform for the future energy system.”

About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI® delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai.

About Royal Dutch Shell plc
Royal Dutch Shell plc is incorporated in England and Wales‚ has its headquarters in The Hague and is listed on the London‚ Amsterdam‚ and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. For further information, visit www.shell.com. The companies in which Royal Dutch Shell plc directly and indirectly owns investments are separate legal entities. In this document “Shell” is sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

C3 AI Public Relations
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai

Investor Relations
ir@c3.ai

Shell Media Relations
Laura van Lingen
+31 (0)70 377 8750
Laura.vanLingen@shell.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye